Skip to main content
S&P 5007,656.98+0.86%DOW52,573.29+0.98%NASDAQ26,333.03+0.96%BTC$77,267.00+0.58%ETH$2,510.86+2.27%GOLD$4,390.00-0.39%OIL$99.99-2.43%
Smart Investors Daily
XE

NASDAQ · XERS

Xeris Biopharma Holdings, Inc.

Healthcare · Biotechnology

$7.67

Down-$0.22 (-2.87%)

Updated Sep 12, 2026, 1:46 AM

SID Score

6.2/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
1.16B
P/E ratio
-34.21
Dividend yield
0.00%
52-week range
$5.25 – $9.02
Volume
1.96M
Avg. volume
2.44M

Price performance

XERS price history

1M range · 19 trading sessions · Daily adjusted prices

XERS closed at $7.67 after 19 trading sessions, down 10.81% for the selected period.

Last close
$7.67
Period change
-10.81%
Period low
$7.67
Period high
$8.85
Daily close
View OHLC price history
XERS OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 10, 2026$7.80$7.99$7.63$7.671.96M
Sep 9, 2026$8.43$8.605$7.64$7.712.82M
Sep 8, 2026$8.39$8.515$8.22$8.481.35M
Sep 4, 2026$8.50$8.585$8.38$8.531.03M
Sep 3, 2026$8.64$8.775$8.415$8.591.6M
Sep 2, 2026$8.49$8.635$8.2746$8.581.35M
Sep 1, 2026$8.42$8.615$8.38$8.431.14M
Aug 31, 2026$8.45$8.485$8.285$8.441.4M
Aug 28, 2026$8.62$8.675$8.37$8.481.03M
Aug 27, 2026$8.62$8.74$8.55$8.601.27M
Aug 26, 2026$8.74$8.89$8.61$8.681.5M
Aug 25, 2026$8.81$8.95$8.665$8.741.01M
Aug 24, 2026$8.66$8.80$8.539$8.74870.74K
Aug 21, 2026$8.61$8.81$8.535$8.701.56M
Aug 20, 2026$8.91$8.985$8.56$8.602M
Aug 19, 2026$8.93$9.02$8.77$8.782.25M
Aug 18, 2026$8.58$8.88$8.47$8.852.14M
Aug 17, 2026$8.45$8.545$8.2589$8.521.33M
Aug 14, 2026$8.33$8.67$8.25$8.601.37M

Latest XERS news

The latest Smart Investors Daily articles mentioning XERS.

Stock researchCompany · Overview

XERS research

Overview

Company profile and research snapshot.

Company profile

Xeris Biopharma Holdings Inc is a biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offer Recorlev for the treatment of Cushing's syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis (PPP).

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$13.50
Implied upside
—
Analysts
12
XERS recent ratings
DateFirmRatingTarget
Sep 10, 2026Leerink PartnersOutperform—
Aug 20, 2026BarclaysOverweight—
Mar 2, 2026HC Wainwright & Co.Buy—
Jan 9, 2026HC Wainwright & Co.Buy—
Dec 9, 2025BarclaysOverweight—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Aug 26, 2026

Xeris Announces Details for XP-8121 Program Overview Webinar

CHICAGO, August 26, 2026--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced details for a dedicated Program Overview webinar for XP-8121, the Company’s Phase 3-ready, once-weekly subcutaneous levothyroxine injection in development for the treatment of hypothyroidism.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By